
Glenmark Pharmaceuticals Ltd. (GLENMARK) Share Price Near 52-Week High on Market Attention
Updated: 18 Nov 2026 • 9:54 am
Posted by:

Glenmark Pharmaceuticals Ltd. Share Price is Rs 2,661.65, up 1.83% today, and it is trading near its 52-week high with a market capitalisation of Rs 74,194.04 crore.
Glenmark Pharmaceuticals Ltd. Share Price opened the morning at Rs 2,665, moved between Rs 2,627.30 and Rs 2,669.40, and was last traded at Rs 2,661.65 as of 18 November 2026 at 9:52 AM IST. The stock is up Rs 47.85, or 1.83%, from the previous close of Rs 2,613.80, while the market capitalisation stands at Rs 74,194.04 crore. That places Glenmark Pharmaceuticals Share Price close to its 52-week high, keeping Glenmark Pharmaceuticals Share Price Today in focus for stock news and share price tracking on Univest.
Glenmark Pharmaceuticals Ltd. Share Price Today: Price Action Analysis
On a simple price basis, Glenmark Pharmaceuticals Share Price is trading only a little below its one-year high area, so the move is notable for readers following Glenmark Pharmaceuticals Stock News and Glenmark Pharmaceuticals Share Price Today. According to latest Univest data, the price event is confirmed, but the figures do not establish a company-specific catalyst. The latest price action is relevant because it shows the stock staying near its yearly high while investors compare Glenmark Pharmaceuticals Share Price with valuation, earnings quality and sector benchmarks. Glenmark Pharmaceuticals Share News and Glenmark Pharmaceuticals Latest News are therefore drawing attention alongside the near 52-week high event.
| Metric | Value |
|---|---|
| Current Price | Rs 2,661.65 |
| Previous Close | Rs 2,613.8 |
| Today's Move | +Rs 47.85 (+1.83%) |
| Open | Rs 2,665 |
| High | Rs 2,669.4 |
| Low | Rs 2,627.3 |
| Market Capitalisation | Rs 74,194.04 crore |
Glenmark Pharmaceuticals Ltd. (GLENMARK) traded at Rs 2,661.65 versus the previous close of Rs 2,613.8, a rise of 1.83%. The stock opened at Rs 2,665, reached a high of Rs 2,669.4 and touched a low of Rs 2,627.3.
Glenmark Pharmaceuticals Ltd. Share Price Today reflects a narrow gap between the day’s low of Rs 2,627.30 and the day’s high of Rs 2,669.40, with the current price at Rs 2,661.65. Compared with the previous close of Rs 2,613.80, the stock is higher by Rs 47.85, which equals 1.83%. The opening price of Rs 2,665 sat close to the upper part of the intraday range, while the share remains near its 52-week high and above its earlier range through the morning. For readers tracking Glenmark Pharmaceuticals Share Price Live, the key point is that today’s move keeps Glenmark Pharmaceuticals Share Price in the 52 Week High Stocks conversation without turning it into a record-high claim.
Why Glenmark Pharmaceuticals Ltd. (GLENMARK) May Be Moving Today
According to recent news reports, Glenmark Pharmaceuticals’ subsidiary has filed an Investigational New Drug application with the US FDA for ISB 2301. That step may be linked to the stock’s strong opening and its position near the yearly high, although the filing itself does not prove causation. The update is specific to the development pathway for the asset and could be relevant for Glenmark Pharmaceuticals Stock News over the near term. For readers following Glenmark Pharmaceuticals News Today and Glenmark Pharmaceuticals Latest News, this is the only verified company-specific item in the last 24 hours and it sits alongside the price move seen in Glenmark Pharmaceuticals Share Price Today.
Glenmark Pharmaceuticals Ltd. (GLENMARK) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 74,194.04 crore |
| P/E Ratio | 50.83x |
| P/B Ratio | 6.58x |
| ROE | 14.1% |
| ROCE | 20.35% |
| EPS | Rs 51.42 |
| Book Value Per Share | Rs 397.29 |
| Dividend Yield | 0.1% |
Glenmark Pharmaceuticals Ltd. (GLENMARK) fundamental metrics show P/E 50.83x, P/B 6.58x, ROE 14.1%, ROCE 20.35%. These figures provide context only and are not a buy or sell signal.
Glenmark Pharmaceuticals Ltd. has a market capitalisation of Rs 74,194.04 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 50.83x, P/B at 6.58x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 14.1% and ROCE of 20.35%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 51.42, book value per share of Rs 397.29, dividend yield of 0.1%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 26.36x, median ROE of 11.22%, median ROCE of 12.76%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 50.83x |
| Benchmark Median P/E | 26.36x |
| Benchmark Average P/E | 50.48x |
| Benchmark P/E Range | 0x to 1,425.63x |
| Company P/B Ratio | 6.58x |
| Benchmark Median P/B | 2.73x |
| Company ROE | 14.1% |
| Benchmark Median ROE | 11.22% |
| Company ROCE | 20.35% |
| Benchmark Median ROCE | 12.76% |
| Company Market Capitalisation | Rs 74,194.04 crore |
| Benchmark Median Market Cap | Rs 747.19 crore |
Glenmark Pharmaceuticals Ltd. (GLENMARK) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.
Glenmark Pharmaceuticals Ltd. (GLENMARK) has a P/E ratio of 50.83x, which is above the benchmark median of 26.36x, a difference of +92.83%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Glenmark Pharmaceuticals Ltd. (GLENMARK) has a ROE of 14.1%, which is above the benchmark median of 11.22%, a difference of +25.67%. Glenmark Pharmaceuticals Ltd. (GLENMARK) has a ROCE of 20.35%, which is above the benchmark median of 12.76%, a difference of +59.48%.
Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Alkem Laboratories Ltd. | ALKEM | 61,456.41 | 29.95 | 4.17 | 18.29 | 21.28 |
| Lupin Ltd. | LUPIN | 90,201.05 | 17.16 | 3.72 | 27.11 | 28.86 |
| Biocon Ltd. | BIOCON | 58,994.93 | 129.64 | 1.68 | 1.35 | 3.26 |
| Gland Pharma Ltd. | GLAND | 55,758.82 | 43.38 | 5.02 | 10.56 | 14.96 |
| Abbott India Ltd. | ABBOTINDIA | 55,148.84 | 33.24 | 12.87 | 34.67 | 46.72 |
Glenmark Pharmaceuticals Ltd. (GLENMARK) has a P/E ratio of 50.83x compared with the displayed peer median of 33.24x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 14.1% compares with a peer median of 18.29% across the companies shown in the table. ROCE stood at 20.35% versus the displayed peer median of 21.28%, providing a capital-efficiency comparison. Glenmark Pharmaceuticals Ltd. (GLENMARK) has a market capitalisation of Rs 74,194.04 crore. Among the 5 peers shown, 1 has a larger market capitalisation.
Why Investors Are Watching Glenmark Pharmaceuticals
- Glenmark Pharmaceuticals Share Price is trading near its 52-week high, with a one-day gain of 1.83%.
- Glenmark Pharmaceuticals Share Price Today is above the previous close by Rs 47.85.
- Glenmark Pharmaceuticals Fundamental Analysis shows a P/E of 50.83 and P/B of 6.58.
- Glenmark Pharmaceuticals Share Price is supported by ROE of 14.1% and ROCE of 20.35%.
- Recent Glenmark Pharmaceuticals Stock News includes a subsidiary filing an IND application with the US FDA.
About Glenmark Pharmaceuticals Ltd.
Glenmark Pharmaceuticals Ltd. operates in the Healthcare sector and the Pharmaceuticals & Drugs industry. Glenmark Pharmaceuticals Share Price is followed on NSE and BSE by readers tracking Glenmark Pharmaceuticals Stock News, Glenmark Pharmaceuticals Share Price Live and Glenmark Pharmaceuticals Company News. The company description in this article is limited to the verified sector and industry classification, which is enough to place Glenmark Pharmaceuticals Share Price in the right market context for this update. Glenmark Pharmaceuticals Latest News, Glenmark Pharmaceuticals Market Cap and Glenmark Pharmaceuticals Share Price Today remain the main reference points in this article.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Registration Number INH000013776), a subsidiary of Univest Communication Technologies Private Limited.
Frequently Asked Questions
Why is Glenmark Pharmaceuticals Share Price near its 52-week high?
Ans. Glenmark Pharmaceuticals Share Price is near its 52-week high because it is trading at Rs 2,661.65, close to its intraday high of Rs 2,669.40. The move is also supported by a 1.83% rise from the previous close.
What is Glenmark Pharmaceuticals Share Price Today?
Ans. Glenmark Pharmaceuticals Share Price Today is Rs 2,661.65. It is higher than the previous close of Rs 2,613.80 and places the stock close to its yearly high zone during the morning session.
How much did Glenmark Pharmaceuticals Share Price move today?
Ans. Glenmark Pharmaceuticals Share Price moved up by Rs 47.85, or 1.83%, from the previous close. The day’s range between Rs 2,627.30 and Rs 2,669.40 shows the stock stayed near the upper part of trading.
What is Glenmark Pharmaceuticals market capitalisation?
Ans. Glenmark Pharmaceuticals Market Cap is Rs 74,194.04 crore. That places the company well above the benchmark median market capitalisation for the same industry and gives scale context to Glenmark Pharmaceuticals Share Price.
How is Glenmark Pharmaceuticals valued on earnings?
Ans. Glenmark Pharmaceuticals Share Price is valued at a P/E ratio of 50.83. That is above the same-industry median of 26.36 and slightly above the benchmark average, so valuation remains an important watchpoint.
What do Glenmark Pharmaceuticals ROE and ROCE show?
Ans. Glenmark Pharmaceuticals reports ROE of 14.1% and ROCE of 20.35%. These figures help compare Glenmark Pharmaceuticals Share Price with sector norms and show returns above the benchmark medians for both measures.
What are the key fundamental numbers for Glenmark Pharmaceuticals Share Price?
Ans. The key numbers are P/B at 6.58, EPS at Rs 51.42, book value at Rs 397.29 and dividend yield at 0.1%. Together they give useful context for Glenmark Pharmaceuticals Share Price and valuation.
What recent news is linked with Glenmark Pharmaceuticals Stock News?
Ans. Recent Glenmark Pharmaceuticals Stock News includes a subsidiary filing an Investigational New Drug application with the US FDA for ISB 2301. The update may be linked with the stock’s near-high price action, though it does not prove causation.
Track Glenmark Pharmaceuticals Ltd. Share Price on Univest
Use Glenmark Pharmaceuticals Ltd. (GLENMARK) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.
You can track Glenmark Pharmaceuticals Share Price on Univest for live price updates, key ratios, 52-week levels, sector comparison, peer context and broader Glenmark Pharmaceuticals Stock Analysis. Univest also helps readers follow Glenmark Pharmaceuticals Share Price Today alongside Glenmark Pharmaceuticals Latest News and Glenmark Pharmaceuticals Financial Results in one place.
Recent Articles

BHADORA INDUSTRIES LTD Hits Lower Circuit for the 2nd Straight Session on NSE, 18 November 2026
18 November 2026

Zeal Global Services Ltd. Hits Upper Circuit on NSE, 18 November 2026
18 November 2026

East India Drums And Barrels Manufacturing Ltd. Hits Upper Circuit on BSE, 18 November 2026
18 November 2026

Magnus Retail Ltd. Hits Upper Circuit on BSE, 18 November 2026
18 November 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
BHADORA INDUSTRIES LTD Hits Lower Circuit for the 2nd Straight Session on NSE, 18 November 2026
Zeal Global Services Ltd. Hits Upper Circuit on NSE, 18 November 2026
East India Drums And Barrels Manufacturing Ltd. Hits Upper Circuit on BSE, 18 November 2026
Magnus Retail Ltd. Hits Upper Circuit on BSE, 18 November 2026
OM FREIGHT FORWARDERS LTD Hits Lower Circuit for the 2nd Straight Session on NSE, 18 November 2026
Popular this week
GAIL (India) Ltd. (GAIL) Share Price near 52-week high as stock trades at Rs 189.10

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





